SPPI News and Press, Spectrum Pharmaceuticals Inc. From 11/10/22

Spectrum Pharmaceuticals, Inc. (SPPI) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Michael Grabow - Executive Vice President of Chief Business Officer Thomas Riga - President and Chief Executive Officer Francois J. Lebel - Ex...

Spectrum Pharmaceuticals press release ( NASDAQ: SPPI ): Q3 GAAP EPS of -$0.12 beats by $0.03 . Shares +1.7% . As of September 30, 2022, the Company had $100.3 million of cash, cash equivalents, and marketable securities available to optimize the ROLVEDON comme...

-- ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available -- -- Cash runway expected to extend through 2024 -- -- Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT -- Spectrum Pharmaceuticals, Inc. (Nas...

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022...

Penny Stocks Trading Higher As Stock Market Sell-Off Continues There has been a brief reprieve from the 2022 stock market crash. The last few weeks of October opened the door for a bounce in the broader market. But continued uncertainty regarding inflation and recessions have kept most ...

NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), F45 Training Holdings, Inc. (NYSE: FXLV), PROG Holdings, Inc. (NYSE: PRG...

Spectrum Pharmaceuticals ( NASDAQ: SPPI ) on Friday said that its medicine Rolvedon was now commercial available. Rolvedon (eflapegrastim-xnst) injection was approved in the U.S. in September to decrease the incidence of infection, manifested by febrile n...

-- Distribution partners stocked with product and ready to sell into estimated $2 billion market -- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology t...

Hours after an FDA advisory panel rejected the company’s lung cancer medication poziotinib, Spectrum Pharmaceuticals ( NASDAQ: SPPI ) announced a five-year debt financing agreement on Friday to secure a term loan worth up to $65M. The company said that its existing ...

-- Multiple tranche debt financing provides Spectrum with up to $65 million -- -- Funding provides additional capital to optimize commercial launch of ROLVEDON™ -- -- Cash runway extended through 2024 -- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SP...